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Recombinant human erythropoietin (rhEPO) is used to treat
anemia in chronic renal insufficiency. Erythropoietin (EPO)
immunogenicity can lead to EPO-resistant anemia.
Conjugating proteins with polyethylene glycol (PEG) can
prolong elimination half-life and diminish protein
immunogenicity. We investigated the efficacy of new
erythropoietic agents, synthesized by single (Ro 50-3821) and
multiple (MIX) integrations of PEG and succinimidyl butanoic
acid with rhEPO, in rats with chronic renal insufficiency.
Sprague–Dawley rats with surgically induced renal
insufficiency received Ro 50-3821 or MIX subcutaneously
(s.c.) over 4–12 weeks compared to rhEPO and NaCl.
Hemoglobin and antibody levels served as primary efficacy
and safety variables. Dosing intervals and dose–response
characteristics were investigated. Ro 50-3821 (2.5 lg/kg once
weekly) increased hemoglobin levels by 7 g/dl after 4 weeks
compared to 1 g/dl in NaCl controls (Po0.05). MIX (2.5 lg/kg
once weekly) and rhEPO (0.25 lg/kg three times weekly)
increased hemoglobin levels by 3 g/dl. Ro 50-3821
administered for 12 weeks (0.75 lg/kg once weekly)
increased hemoglobin levels (from 13 to 19 g/dl) more
effectively than rhEPO (0.75 lg/kg once weekly, decline from
13 to 11 g/dl, Po0.05). No antibodies against Ro 50-3821
were detected after 12 weeks of treatment. Antibodies
against rhEPO were seen in 69% of animals (Po0.00001).
Ro 50-3821 increased hemoglobin levels with once weekly
s.c. dosing. Multiple pegylated EPO is less effective. In rats,
rhEPO failed to increase hemoglobin levels with once weekly
long-term dosing. Antibody formation following rhEPO may
explain this finding. Therefore, Ro 50-3821 may provide
important clinical advantages compared to unpegylated EPO.
It can be administered in longer dosing intervals and has a
lower risk of unfavorable immunological responses.
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Renal anemia is a common complication in patients with
chronic renal failure (CRF).1,2 There is a direct relationship
between the decline in renal function and the severity of the
anemia.3 This anemia significantly contributes to morbidity-
causing symptoms such as lack of energy, breathlessness,
dizziness, angina, poor appetite, and decreased exercise
tolerance.4,5 The decreased production of erythropoietin
(EPO), a hormone mainly produced by the kidney, has been
identified as the main cause of anemia in CRF.6 Up to the late
1980s, iron and folate were the main treatments for anemia in
these patients. If these treatments failed, patients were
dependent on blood transfusions, with their associated risks
of transmission of infectious diseases.
In 1985, the cloning of the human gene for EPO was
achieved by Lin et al.7 Production of recombinant human
EPO (rhEPO) followed and, soon after, the efficacy of rhEPO
treatment in dialysis patients was first demonstrated in
clinical trials.8,9 Since then, rhEPO has become an integral
part in the treatment of patients with CRF. It has been shown
to correct anemia to acceptable levels, with improvements in
the quality of life of patients and a reduced risk for
comorbidity.10–13 In patients not yet on dialysis, it has been
proposed that EPO may slow progression of renal disease,
but this is still a matter of debate.14 In a relatively limited
number of predialysis patients with nonsevere anemia, early
initiation of EPO significantly slowed the progression of renal
disease and delayed the initiation of renal replacement
therapy.15
However, in approximately 5–10% of patients, therapy
with rhEPO does not lead to an effective stimulation of
erythropoiesis.16 The reasons are diverse17 and include
absolute or functional iron deficiency,18 as well as a lack of
compliance if EPO has to be injected at least three times per
week in patients with CRF.19 Antibody production against
EPO, resulting in EPO-resistant anemia,20–22 may play a role
in a small number of patients. Less frequent dosing schemes
have been a therapeutic goal in anemia-correcting therapy in
patients with CRF.23 This may be achieved by increasing the
half-life of the used therapeutic agent.24,25 Altering the dosing
schemes has been employed successfully in patients with
cancer or chronic hepatitis C treated with pegylated
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interferon-alpha-2b, which may present a way of improving
therapeutic efficacy.26 In patients with chronic renal dysfunc-
tion, pegylated interferon-alpha-2b can also be administered
safely and with a favorable pharmacokinetic profile.27 In
addition, pegylated proteins may reduce the immunogenicity
of the parent protein.28,29 So far no in vivo characterization of
pegylated EPO pharmacodynamics is available. We therefore
investigated the therapeutic efficacy, possible dosing schemes,
and the immunogenicity of different erythropoietic agents
synthesized by integration of polyethylene glycol (PEG) in
comparison to conventional rhEPO in Sprague–Dawley rats
with CRF.
RESULTS
Efficacy (protocol 1)
Ro 50-3821 and MIX in doses of 2.5 mg/kg body weight (bw)
administered once per week as well as conventional
recombinant rhEPO (0.25 mg/kg bw administered three times
per week) increased mean hemoglobin levels after 4 weeks of
treatment. The largest effect was seen in rats receiving Ro 50-
3821 2.5 mg/kg bw, in which hemoglobin levels rose from
13.471.4 to 19.571.8 g/dl (Po0.05 in comparison to NaCl
control). Hemoglobin levels following conventional rhEPO
therapy remained significantly lower than after Ro 50-3821
and MIX in doses of 2.5 mg/kg bw (Po0.05 for both
comparisons). After 4 weeks of isotonic saline, Ro 50-3821,
or MIX in doses of 0.25 mg/kg bw, hemoglobin levels were
unchanged (Figure 1).
Red blood count (RBC) and hematocrit measurements
correlated strongly with changes in hemoglobin levels.
Reticulocyte counts were not influenced by low-dose Ro
50-3821, MIX, or saline. rhEPO increased reticulocyte counts
over the first week of treatment, but reticulocyte counts
receded to baseline levels after 4 weeks of treatment. In
contrast, Ro 50-3821- and MIX- (2.5 mg/kg bw once weekly)
treated animals continued to show increased reticulocyte
counts after 4 weeks of treatment. These changes were
statistically significant compared to NaCl controls as well as
rhEPO therapy (Figure 2).
Blood pressure levels were alike in all treatment groups.
None of the drugs in the administered doses significantly
increased systolic blood pressure. Similarly, no significant
differences in white blood count, serum electrolytes, renal
function parameters, and liver function tests were seen after
treatment with either of the study drugs.
Dosing scheme (protocol 2)
rhEPO and Ro 50-3821 in doses of 0.75 mg/kg bw
administered once weekly, as well as Ro 50-3821 at a dose
of 0.25 mg/kg bw, were associated with a moderate increase in
hemoglobin levels compared to saline controls (Table 1).
These changes, however, were not significant. Only conven-
tional rhEPO administered three times per week yielded a
substantial increase in hemoglobin levels from 12.971.1 g/dl
at baseline to 17.071.3 g/dl (Po0.05 compared to saline and
all other treatment groups).
Systolic blood pressure levels ranged from 134 to
146 mmHg during protocol 2. No significant differences
between treatment groups were noted. Similarly, there were
no significant differences in white blood count, serum
electrolytes, renal retention parameters, and liver function
tests after treatment with either of the study drugs.
Long-term efficacy and safety (protocol 3)
In this protocol investigating the long-term erythropoietic
properties of three different Ro 50-3821 doses as well as
conventional rhEPO, the two high-dose Ro 50-3821 arms (2.5
and 7.5 mg/kg bw once weekly) were terminated after 8 weeks
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Figure 1 | Mean hemoglobin levels after respective weeks of
treatment. All doses are expressed as mg/kg bw. Pegylated EPO
derivatives (Ro 50-3821 and MIX) and physiologic saline were
administered once weekly. Conventional rhEPO (0.25 mg/kg) was
administered three times per week. For the number of animals in
each dosing group, refer to Table 3. *Po0.05 compared to saline
control.
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Figure 2 | Mean reticulocyte counts after respective weeks of
treatment. All doses are expressed as mg/kg bw. Pegylated EPO
derivatives (Ro 50-3821 and MIX) and physiologic saline were
administered once weekly. Conventional rhEPO (0.25 mg/kg) was
administered three times per week. For the number of animals in
each dosing group, refer to Table 3. *Po0.05 compared to saline
control.
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instead of the initially planned 12 weeks. This was done due
to the steadily increasing hematocrit levels impairing animal
well-being. The lower-dose Ro 50-3821 and rhEPO arm
(0.75 mg/kg bw once weekly) as well as the NaCl control arm
were terminated as originally planned. Inferential statistics
were determined only on these study arms. The results of the
prematurely terminated study arms are presented with
descriptive statistics only.
Erythropoiesis
Ro 50-3821 (0.75 mg/kg bw administered once weekly)
steadily increased hemoglobin levels from 13.470.5 g/dl
prior to study medication to 16.071.2 after 4 weeks and
18.772.1 g/dl after 12 weeks of treatment (Po0.05 com-
pared to saline controls). In contrast, rhEPO (0.75 mg/kg bw
administered once weekly) failed to increase hemoglobin
levels over the period of 12 weeks. After a temporary increase
from 12.971.1 g/dl at baseline to 15.971.9 g/dl following 4
weeks of treatment, hemoglobin levels dropped to
11.374.6 g/dl after 10 weeks and 11.273.6 g/dl after 12
weeks of treatment (Po0.05 compared to Ro 50-3821
0.75 mg/kg bw).
Similarly to hemoglobin concentrations, the erythrocyte
count rose steadily under Ro 50-3821 0.75 mg/kg bw and
became significantly higher than in rats receiving saline
control solution after 4, 8, 10, and 12 weeks of treatment.
Again, rhEPO failed to produce a lasting effect on RBC
(Figure 3).
Antibody response
Ro 50-3821 (0.75 mg/kg bw administered once weekly) did
not lead to a positive antibody response in any of the 13
animals after 12 weeks of treatment. Within this time frame,
rhEPO administered in the same dosing scheme had led to
significant antibody production in over 64% of all rats
(Po0.0001 compared to Ro 50-3821 and NaCl; Table 2). This
effect was already detected after 8 weeks of treatment. In a
‘worst-case scenario’, where animals that died during the
study were counted towards the group of antibody-positive
animals, 71% of animals showed a positive immunological
reaction against rhEPO.
Safety parameters
Systolic blood pressure rose in all treatment groups between
weeks 2 and 4 of treatment. An increase of 32 mmHg was
measured for the high-dose Ro 50-3821 (7.5 mg/kg bw) group
by week 4. rhEPO increased systolic blood pressure by
22 mmHg, whereas the low-dose Ro 50-3821 (0.75 mg/kg bw)
as well as the control animals yielded an increase in systolic
blood pressure of 17 mmHg by week 4. In all groups treated
for 12 weeks, blood pressure levels decreased after week 4 and
reached levels comparable to baseline by week 12.
Again, there were no significant differences in white blood
count, serum electrolytes, renal function parameters, and
liver function tests after treatment with either of the study
drugs.
DISCUSSION
Erythropoietic efficacies of Ro 50-3821 and MIX, synthesized
by single and multiple linkage of rhEPO with PEG,
respectively, were investigated and compared to the efficacies
of rhEPO and saline control in the first protocol of this study.
Ro 50-3821 was more effective than MIX in stimulating
erythropoiesis. A Ro 50-3821 dose of 2.5 mg/kg bw adminis-
tered once weekly was superior to MIX at the same dose and
rhEPO in the recommended dose for treatment of anemia in
CRF (0.25 mg/kg bw administered three times per week30).
The increase following rhEPO is in line with earlier findings
in rats and other species.31,32 Ro 50-3821, the more effective
of the agents tested, showed comparable erythropoiesis-
stimulating efficacy to rhEPO in the second protocol. Both
Table 1 | Hemoglobin concentrations, protocol 2
Medication Week
Hemoglobin
(g/dl) Medication Week
Hemoglobin
(g/dl)
rhEPO 0.25 0 12.971.1 Ro 50-3821 0.25 0 13.171.2
rhEPO 0.25 1 14.971.3 Ro 50-3821 0.25 1 14.970.9
rhEPO 0.25 2 16.271.3 Ro 50-3821 0.25 2 14.571.0
rhEPO 0.25 3 16.871.6 Ro 50-3821 0.25 3 15.071.2
rhEPO 0.25 4 17.071.3 Ro 50-3821 0.25 4 15.271.3
rhEPO 0.75 0 12.770.8 Ro 50-3821 0.75 0 13.670.6
rhEPO 0.75 1 14.670.8 Ro 50-3821 0.75 1 15.270.8
rhEPO 0.75 2 14.771.3 Ro 50-3821 0.75 2 14.770.9
rhEPO 0.75 3 15.171.0 Ro 50-3821 0.75 3 15.170.8
rhEPO 0.75 4 15.271.0 Ro 50-3821 0.75 4 15.770.9
NaCl 0 12.971.1
NaCl 1 14.270.5
NaCl 2 13.870.5
NaCl 3 14.070.6
NaCl 4 13.870.7
Values are presented as mean7s.d. Medication doses are expressed as mg/kg bw.
Low doses of rhEPO and Ro 50-3821 were administered three times weekly;
physiologic NaCl controls as well as high doses of rhEPO and Ro 50-3821 were
administered once weekly.
Red blood count, protocol 3
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Figure 3 | Mean RBC after respective weeks of treatment. All
doses are expressed as mg/kg bw. All medications were administered
once weekly. For the number of animals in each dosing group, refer
to Table 3. *Po0.05 compared to saline control.
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compounds were administered three times per week in a dose
of 0.25 or once weekly in a dose of 0.75 mg/kg bw (Table 1).
This may suggest maximal stimulation of erythropoiesis
already with the low dose of both drugs under the conditions
used. In protocol 3, the long-term arm of this study, Ro 50-
3821 was superior to rhEPO in augmenting the parameters of
erythropoiesis (hemoglobin levels, RBC, and hematocrit) at a
dose of 0.75 mg/kg bw administered once weekly. After 12
weeks of treatment, hemoglobin levels were 18.7 mg/dl
following Ro 50-3821 compared to 11.2 mg/dl in rats
receiving rhEPO (Po0.05). In our rats, rhEPO also failed
to increase other parameters of erythropoiesis over this
prolonged period of time. A decline and/or time-limited
increase in RBC count in dogs and rats has been described
following rhEPO.33 With an extended duration of exposure,
neutralizing antibodies have been suggested to blunt the
pharmacological action of rhEPO. No other clinical or
postmortem observations were made in this study to explain
the reduced rhEPO response. Ro 50-3821 was clearly effective
in boosting erythropoiesis in rats with chronic renal
insufficiency. In dosing schemes with multiple injections
per week, rhEPO had shown a beneficial effect on
erythropoiesis in chronically renal insufficient rats31 and
humans.9,10 Therefore, it may be hypothesized that rhEPO
may have matched the erythropoiesis-stimulating effect of Ro
50-3821 if it had been administered more frequently. In a
clinical setting, however, more frequent dosing, especially if
unpleasant, usually corresponds to decreased compliance.
Decreased compliance, in turn, may limit treatment suc-
cess.34 In addition, it is easily conceivable that frequent
injections impair patients’ quality of life.35 Therefore, a less
difficult and less unpleasant dosing scheme in patients with
CRF may entail increased compliance with treatment and
enhance the quality of life.
Another important aspect in choosing a drug for a patient
is the safety profile of the drug. In this animal model of CRF,
neither of the investigated drugs seemed to be particularly
problematic. Blood pressure was largely unchanged. It is
unlikely that the observed increase in protocol 3 at week 4 is
attributable to the erythropoietic agents, as control animals
showed a comparable increase at that time point only. Blood
chemistry, white blood cell and thrombocyte count, liver
function tests, and renal retention parameters were largely
unaffected by the examined drugs. Since no effects on any but
the red blood cell line were noted, the novel erythropoietic
agents seem to exert specific qualities. All changes of safety
parameters observed were within the range seen in saline-
treated control animals.
During protocol 3, one animal from the rhEPO group was
found dead, and nine animals had to be killed (four from the
middle-dose and four from the high-dose Ro 50-3821
groups, and one from the control group). Paralyses, cramps,
a bad general condition, deteriorating renal function, and a
decrease or a reduced increase in body weight were observed.
These findings are probably due to uremia, which in turn
might be aggravated by rheological changes due to the very
high hematocrit in these animals.36,37 A distinct interindivi-
dual variation is immanent in this animal model, caused by
variability of five-sixths nephrectomy. Owing to the complex-
ity of the test situation, the assessment of toxicity findings
and deaths of animals demands caution.
Postmortem tissue examinations revealed extramedullar
erythropoiesis in all middle- and high-dose Ro 50-3821-
treated rats and in two of the 12 rhEPO-treated rats, but in
none of the animals treated with the low-dose Ro 50-3821.
This exaggerated pharmacological response substantiates the
proposal that subcutaneous (s.c.) Ro 50-3821 at doses of 2.5
and 7.5 mg/kg bw leads to an extremely pronounced
stimulation of erythropoiesis with its untoward conse-
quences.
However, in the light of available data, it seems legitimate
to propose that the tested Ro 50-3821 has a safety profile at
least as favorable as that of conventional rhEPO. This
proposal is fuelled by the promising results on antibody
formation following administration of the various com-
pounds. Antibodies were found in the high-dose group of Ro
50-3821 in one out of nine animals and in rhEPO-treated
animals in nine out of 14 animals. The much more
pronounced antibody formation with rhEPO, within all
inherent limitations of animal models in this context,
suggests reduction of immunogenicity by the modification
used. It has been suggested that antibody formation following
Table 2 | Antibody response, protocol 3
Week 12 Week 10 Week 8
Dose
(lg/kg bw)
Antibodies
present
Antibodies
not present
Antibodies
present
Antibodies
not present
Antibodies
present
Antibodies
not present
Ro 50-3821 0.75 0 13 0 13 0 13
Worst case 0 13 0 13 0 13
rhEPO, 0.75 9*,z 5 9*,z 4 9*z 4
Worst case 9*,z 5 10*,z 4 10*,z 4
NaCl (0.9%) 0 11 0 11 0 11
Worst case 1 11 1 11 1 11
Ro 50-3821 2.5 0 7
Ro 50-3821 7.5 1 8
Medication was administered once weekly. Ro 50-3821 2.5 and Ro 50-3821 7.5 study arms were terminated after 8 weeks. All others continued for 12 weeks. Inferential
statistics were calculated only for the latter three study arms. *Po0.05, **Po0.0001 compared to controls. zPo0.0001 compared to Ro 50-3821 0.75.
Worst case displays a scenario in which animals that died are added to the category ‘antibodies present’.
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s.c. rhEPO is related to the used vehicle and is only seen after
s.c. injection of epoetin alpha in Caucasians. However,
recently it has been recognized that other EPO derivatives
may lead to antibody formation and also that other ethnic
groups may be afflicted.38 The entire extent and clinical
significance of anti-EPO antibodies is still unclear and a
matter of debate.39
Although not a major clinical concern in the treatment of
patients with CRF, Ro 50-3821 may help to avoid cases of
rhEPO resistance20–22,40 and decrease the incidence of pure
red cell aplasia40 further.
The findings presented in this study together with those
described elsewhere41,42 show that Ro 50-3821 provides an
important therapeutic benefit compared to currently used
treatment regimens in patients with CRF.
Differences in the binding characteristics compared to
those of rhEPO have been described for Ro 50-3821.41 A
prolonged, dose-dependent, and potent enhancement of
erythropoietic activity was shown for Ro 50-3821 in the first
human studies,43 indicating the relevance of the findings in
animal experiments for humans.
Furthermore, the long-term costs associated with three
injections per week are substantially higher than for single
weekly injections.44
All these aspects will play an important role in future
health care considerations.
CONCLUSIONS
In rats with CRF, Ro 50-3821, rhEPO conjugated with a
single PEG molecule, is capable of correcting anemia. It
increases crucial parameters such as hemoglobin levels,
erythrocyte and reticulocyte count, and hematocrit to
acceptable levels. This can be achieved with only one dose
per week. EPO, with multiple linkage to PEG (MIX), is also
effective, but to a lesser degree.
The safety profile of the novel EPO derivative Ro 50-3821
seems to be superior to that of rhEPO. No significant
antibody formation or increase in blood pressure was found
during treatment with Ro 50-3821, whereas rhEPO induced
significant antibody production in a large percentage of
animals.
Therefore, Ro 50-3821 may offer important clinical
advantages compared to currently used agents, since it could
be administered less frequently, may have a favorable safety
profile, and/or entails a lower risk of unfavorable immuno-
logical responses.
MATERIALS AND METHODS
Before commencement, the study was approved by the Regional
Commission, Karlsruhe, Germany. All experiments were performed
in accordance with federal and local laws, as well as institutional
regulations.
Male Sprague–Dawley rats, 14 weeks old (Janvier, France),
weighing between 300 and 400 g, were fed standard rat chow (Ssniff,
Soest, Germany) ad libitum with free access to tap water for
drinking. All rats were two-thirds nephrectomized unilaterally by
resection of both kidney poles, followed by a complete contralateral
nephrectomy 2 weeks later45 under intraperitoneal ketamine
(Hostakets, Germany; 75 mg/kg bw) and xylazine (Rompuns
2%, Bayer, Germany; 5 mg/kg bw) anesthesia.
The animals were allowed to recover from surgery for about 2
weeks. Thereafter, rats were trained for 1 week for systolic blood
pressure measurements by tail cuff manometry using a commercially
available tail sphygmomanometer (Hugo Sachs Elektronik, March,
Germany).
Baseline blood sampling and premedication-phase blood pres-
sure recordings were begun in the following week. Blood samples
were obtained from the retrobulbar region under ether anesthesia.
Hematocrit, hemoglobin, and erythrocyte, leucocyte, and thrombo-
cyte counts were measured using a Cell Dyn 3500 automated
hematology analyzer (Abbott, Wiesbaden, Germany). Reticulocytes
were measured with an EPICS XL-MCL flow cytometer (Coulter
Electronics, Krefeld, Germany, staining with thiazole orange).
Creatinine, urea, aspartate aminotransferase, alanine aminotransfer-
ase, and alkaline phosphatase were determined with a Hitachi
Automatic Analyzer.
For antibody determination, the enzyme-linked immunosorbant
assay (ELISA) used in the present study as reference method is
described fully elsewhere.46 Briefly, 96-well polystyrol plates coated
with streptavidin (Roche, Basel, Switzerland) were incubated with
125 ml biotinylated rhEPO in sodium phosphate 40 mM, pH 7.4
(Na2HPO4 and NaH2PO4  1 H2O containing 0.1% (v/v) Tween 20
(phosphate buffer (PB))). After washing three times with PB, the
serum samples were added in duplicate 1:25 diluted in PB (without
Tween 20) containing 0.5% bovine serum albumin (BSA), 2% sheep
immunoglobulin (IgG), and 150 mM NaCl. After 3 h of incubation
at room temperature (RT), the plates were washed three times with
PB and subsequently incubated with sheep anti-rat Fab fragments
conjugated with horseradish peroxidase 15 mU/ml final concentra-
tion, 1 h, RT). The substrate 2,20-acino-di(3-ethylbenz-thiazoline-
sulfonic) acid was added and, after 30 min of incubation at RT, the
reaction was read at 405 and 492 nm using SLT microplate Reader
SLT (SLT-Labinstruments GmbH, Gro¨dig/Salzburg, Austria). To
evaluate the specificity of the ELISA, the test was performed in
parallel using BSA or rhEPO (100 mg/ml).
To test the reliability of each run, a dose–response curve of the
control material was used. The control material is a conjugate of
polyclonal anti-erythropoietin antibody from rabbit and human
IgG. Three concentrations (5, 10, and 15 mg/ml) and zero control
material were used to test the reliability of the reaction. The cutoff
point for positive samples was previously evaluated as an absorbance
decrease of 50%. The intra-assay coefficient of variation was 4.2%
(n¼ 20) for absorbance and 5.4% (n¼ 10) for absorbance decrease
(displacement).
The rats were randomly allocated to one of the three study
protocols designed to investigate the pharmacodynamic properties
of the different study drugs. The protocols consecutively examined
the efficacy, frequency of administration, and dose–response
characteristics. After allocation, the rats were given the first dose
of medication according to the respective protocols.
Drugs
The drugs tested in these experiments were rhEPO (epoetin,
working standard, Roche Diagnostics GmbH, Mannheim,
Germany), Ro 50-3821, and an alternative compound (MIX). Ro
50-3821 and MIX were synthesized at Roche, Nutley, NJ, USA, and
are chemically synthesized continuous EPO receptor activators.
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These differ from EPO through integration of amide bonds between
amino groups and methoxy PEG-succinimidyl butanoic acid.41
Scheme of Ro 50-3821 and alternative compound MIX:
[CH3 O(CH2 CH2O)n CH2 CH2 CH2CO]m-NH-EPO
Ro 50-3821 and MIX differ among themselves in the content or
proportion of methoxy PEG-succinimidyl butanoic acid (m).
Physiologic NaCl solution was used as control. To prevent
unspecific binding to surfaces, 0.125 ml freshly prepared blood
serum of Sprague–Dawley rats was added per mg protein of each
EPO medication. All study treatments were administered by s.c.
injection.
Protocol 1
Protocol 1 was performed to investigate the erythropoietic efficacy
of Ro 50-3821 and MIX in comparison to rhEPO and NaCl control.
Rats were randomly allocated to one of six groups. All animals
received the respective study medication for 4 weeks. Group 1
(n¼ 11) received Ro 50-3821 (0.25 mg/kg bw) once per week, group
2 (n¼ 11) received Ro 50-3821 (2.5 mg/kg bw) once per week, group
3 (n¼ 13) received MIX (0.25 mg/kg bw) once per week, group 4
(n¼ 11) received MIX (2.5 mg/kg bw) once per week, group 5
(n¼ 11) received rhEPO (0.25 mg/kg bw) three times per week, and
group 6 (n¼ 10) received NaCl once per week. Blood samples
obtained at the end of each week were analyzed as described above.
After the last set of procedures, following 4 weeks of treatment, rats
were killed under combined ketamin and xylazin anesthesia.
Protocol 2
During protocol 2, Ro 50-3821, the more effective of the two newly
synthesized agents from protocol 1, was tested to characterize the
most suitable frequency of application in comparison to rhEPO and
NaCl (Table 3). Rats were randomly allocated to one of five groups.
Group 1 (n¼ 12) received a low dose of Ro 50-3821 (0.25 mg/kg bw)
three times per week. Group 2 (n¼ 12) received 0.75 mg/kg bw of Ro
50-3821 once weekly. Analogously, groups 3 and 4 received
respective doses of rhEPO (n¼ 12 for both), and group 5 (n¼ 11)
was administered isotonic saline solution once weekly.
Blood samples were obtained at the end of each week of
treatment and animals were killed under combined ketamin and
xylazin anesthesia after 4 weeks of treatment.
Protocol 3
The long-term effects of Ro 50-3821 in regular doses (0.75mg/kg bw
once weekly; n¼ 13) as well as two high doses (2.5 and 7.5 mg/kg bw
once weekly; n¼ 13 for both) were compared to rhEPO (0.75 mg/kg
bw once weekly; n¼ 14) and NaCl in protocol 3. Blood samples for
the determination of hematological parameters were obtained after
1, 2, 4, 6, 8, 10, and 12 weeks of treatment. Antibody levels against
the study drugs were measured after 1, 8, 10, and 12 weeks of
treatment. Rats receiving Ro 50-3821 2.5 and 7.5 mg/kg bw were
killed after 8 weeks of treatment, whereas the Ro 50-3821 0.75 mg/kg
Table 3 | Dose and frequency of study drug administration
Drug dose (lg/kg body weight)
Frequency of
administration
Protocol 1
Ro 50-3821 0.25 (n=11) Once per week
Ro 50-3821 2.5 (n=11) Once per week
MIX 0.25 (n=13) Once per week
MIX 2.5 (n=11) Once per week
rhEPO 0.25 (n=12) Three times per week
NaCl (n=10) Once per week
Protocol 2
Ro 50-3821 0.25 (n=12) Three times per week
Ro 50-3821 0.75 (n=12) Once per week
rhEPO 0.25 (n=12) Three times per week
rhEPO 0.75 (n=12) Once per week
NaCl (n=11) Once per week
Protocol 3
Ro 50-3821 0.75 (n=13) Once per week
Ro 50-3821 2.5 (n=13) Once per week
Ro 50-3821 7.5 (n=13) Once per week
rhEPO 0.75 (n=14) Once per week
NaCl (n=12) Once per week
n=number of animals in each dosing group.
Table 4 | Timeline of protocols 1–3
Study day Protocol 1 Protocol 2 Protocol 3
42 2/3 nephrectomy (left) 2/3 nephrectomy (left) 2/3 nephrectomy (left)
35 Total nephrectomy (right) Total nephrectomy (right) Total nephrectomy (right)
14 Blood sampling (week 0) Blood sampling (week 1)
 7 First dose of study drug Blood sampling (week 0) Blood sampling (week 0)
0 First dose of study drug First dose of study drug
Action taken
Weeks after
initiation of
study drug
Protocol 1 Protocol 2 Protocol 3
1 Blood sampling Blood sampling Blood sampling, antibody levels
2 and 3 Blood sampling Blood sampling
4 Blood sampling, sacrifice Blood sampling, sacrifice Blood sampling
Blood sampling
8 Blood sampling, antibody levels
Killing of rats receiving Ro 50-3821 2.5 and 7.5mg/kg
10 Blood sampling, antibody levels
12 Blood sampling, antibody levels, killing
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as well as the control groups were continued until 12 weeks after
initiation of study medication.
Table 4 shows the timeline of the protocols, and Table 3
summarizes the doses used during their various stages.
Statistical methods
The results of the three protocols were analyzed independently from
one another. Primary evaluation parameters were blood hemoglobin
levels after the respective periods of treatment (4 weeks in protocols
1 and 2, 12 weeks in protocol 3). Values are presented as
means7s.d. Initial analyses compared the means using general
linear models. In case of Po0.05, least-square differences were
calculated, correcting for multiple comparisons, to analyze the
differences between the groups. Statistical analyses were performed
using SASs for Windows version 8.1 (Cary, NC). In secondary
analyses, additional variables characterizing erythropoiesis (RBC,
reticulocyte count, hematocrit) were analyzed using the same
statistical approach. In addition, all parameters were measured
and analyzed after each week of treatment.
In protocol 3, antibody production was analyzed as a dichotomous
variable (antibodies against the respective medication present/not
present). Differences between groups were analyzed using the w2 test
with post hoc decomposition. In case of cell counts smaller than five,
Fisher’s exact test was used.
Animals that died during the treatment phase of protocol 1 were
excluded from analyses (three in the rhEPO and one in the MIX
(0.25mg/kg bw) groups). During protocol 2, no animal was lost.
During protocol 3, nine animals had to be killed and one died (four
in Ro 50-3821 (2.5 mg/kg bw), four in Ro 50-3821 (7.5 mg/kg bw),
one in rhEPO (0.75 mg/kg bw), and one in the control group).
Animals were used for analysis until the date of death. In addition to
the above-outlined analyses, a worst-case scenario analysis was
performed for antibody status. For this purpose, animals that died
were added to the group of animals in which antibodies were
detected.
All safety parameters were evaluated descriptively.
The statistician was blinded with respect to medication while
performing the statistical analyses.
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